Two former executives at Immuomedics were charged with insider trading by U.S. authorities in connection with information about late-stage clinical trial results of a promising cancer drug, which later prompted Gilead Sciences (GILD) to buy the company.
Usama Malik, who had been chief financial officer, and Lauren Wood, the former chief communications officer, were arrested for purchasing Immunomedics stock shortly before positive trial results were released publicly in April 2020. At the time, the pair was romantically involved and lived together in Washington, D.C., according to a criminal complaint filed in federal court in New Jersey.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
